Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFYL51
|
|||
| Drug Name |
Ociperlimab
|
|||
| Synonyms |
BGB-A1217
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [1] | |
| Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 2 | [2] | ||
| Company |
BeiGene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | V-set and immunoglobulin domain-containing protein 9 (TIGIT) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04746924) A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04693234) AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of BeiGene. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.